Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

7.1%

1 terminated/withdrawn out of 14 trials

Success Rate

91.7%

+5.2% vs industry average

Late-Stage Pipeline

71%

10 trials in Phase 3/4

Results Transparency

82%

9 of 11 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

Phase 4
10(71.4%)
Phase 2
3(21.4%)
N/A
1(7.1%)
14Total
Phase 4(10)
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials
NCT07313072Phase 2Not Yet Recruiting

Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study

Role: lead

NCT07273916Phase 2Not Yet Recruiting

Evaluation of the Efficacy and Onset of Action of a Topical Anesthetic Marker

Role: lead

NCT01004042Phase 4Completed

Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients

Role: lead

NCT01027793Phase 4Completed

Trial Comparing Treatment of Tretinoin or Superficial Dermabrasion for Stretch Marks

Role: lead

NCT01732809Phase 4Completed

Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses

Role: lead

NCT01032954Phase 4Completed

Safety and Efficacy of the Full Face Applications of Variable Doses of a Commercial Botulinum Toxin Type a (Dysport®)

Role: lead

NCT01778179Not ApplicableCompleted

A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy

Role: lead

NCT01066026Phase 2Completed

Safety and Efficacy of a Metallic Cannula Versus A Standard Needle for Soft Tissue Augmentation of the Nasolabial Folds

Role: lead

NCT01728337Phase 4Completed

Phase IV Study On Muscle Activity Of Two Commercial Preparations Of Botulinum

Role: lead

NCT01774396Phase 4Completed

Use Of Three Commercial Preparations Of Injectable Hyaluronic Acid In Hands Rejuvenation

Role: lead

NCT00989768Phase 4Completed

Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A

Role: lead

NCT00959907Phase 4Completed

Comparison of Two Commercial Preparations of Botulinum Toxin Type A

Role: lead

NCT00399828Phase 4Terminated

Evaluation Of The Efficacy and Safety Of Tri-ActiveTM In Treatment Of Cellulite

Role: lead

NCT00399854Phase 4Completed

Evaluation of the Efficacy of Endermologie in Treatment of Cellulite and Body Contouring

Role: lead

All 14 trials loaded